Compass Pathways PLC (CMPS) stock experiences periodic downward pressure and high volatility because it is a clinical-stage biotechnology enterprise that remains unprofitable and cash-flow negative. As a developer of novel synthetic psilocybin therapies for mental health disorders, the company relies heavily on extensive research and development spending without commercial product revenue. Market pullbacks frequently occur due to broader biotech sector risk-off sentiment, high capital burn rates, ongoing dilution risks from financing activities, and the speculative nature of waiting for clinical trial milestones and regulatory approvals.